Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806602 | 0.87 | HRH3 (0.48) | HRH3MGLLKMT2A | |
| SCHEMBL1806794 | 0.84 | HRH3 (0.48) | HRH3MGLLCHRNA7KMT2A | |
| SCHEMBL1806615 | 0.83 | HRH3 (0.46) | HRH3MGLLCHRNA7KMT2A | |
| SCHEMBL1808760 | 0.82 | HRH3 (0.50) | HRH3KMT2AKCNH2MCHR1 | |
| SCHEMBL1810819 | 0.82 | HRH3 (0.43) | HRH3MGLLCHRNA7KMT2AOXTR | |
| SCHEMBL1806622 | 0.81 | OXTR (0.55) | HRH3CHRNA7OXTR | |
| SCHEMBL1809068 | 0.80 | OXTR (0.46) | HRH3CHRNA7OXTR | |
| SCHEMBL1807163 | 0.80 | CHRNA7 (0.56) | HRH3MGLLCHRNA7KMT2AOXTR | |
| SCHEMBL1807265 | 0.80 | HRH3 (0.48) | HRH3MGLLKMT2A | |
| SCHEMBL1808742 | 0.80 | OXTR (0.56) | HRH3CHRNA7OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | HRH3 1010/4885MGLL 4513/4885CHRNA7 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.